Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 131 Beijing 124 Shanghai 86 Changsha 72 Fuzhou 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shanghai Chest Hospital12 Sichuan Baili Pharmaceutical Co., Ltd.8 Shanghai Pulmonary Hospital, Shanghai, China7 Fudan University6 Ruijin Hospital3
Site location
Guangzhou131 Beijing124 Shanghai86 Changsha72 Fuzhou59
All 110 locations
Target enrolment
to

Trials with a site in Shanghai

86 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
RemeGen Co., Ltd.
Phase 1/2
26
Shanghai
2027-12-01
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
436
Shanghai, Hangzhou
2026-12
Not yet open
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
NCT07889297Non-Small Cell Lung Cancer, Pulmonary Metastases
Shanghai Chest Hospital
Not applicable
15
Shanghai
2026-10
Not yet open
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
NCT07698990Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Not applicable
1,200
Shanghai
2026-08-21
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
90
Shanghai
2026-07-24
Recruiting
Akeso
Phase 1/2
265
Shanghai
2026-07-07
Not yet open
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
NCT07699757Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
DrugsHSK41959·Cisplatin/Carboplatin·Sintilimab·Nab-paclitaxel
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
258
Shanghai
2026-07
Recruiting
Shanghai Juncell Therapeutics
Phase 2
28
Shanghai
2026-06-01
Not yet open
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Not yet open
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
NCT07558200Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
DrugTEV-56278
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
138
Shanghai
2026-05-15
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
45
Shanghai
2026-04-01
Recruiting
Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
NCT07564557Non-small Cell Lung Cancer, Early-stage Lung Cancer, Deep-seated Lung Nodules, Solid-dominant Lung Cancer
Shanghai Chest Hospital
Not applicable
89
Shanghai
2026-04-01
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Shanghai, Hangzhou
2026-03-18
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Taizhou
2026-01-30
Recruiting
Shanghai Henlius Biotech
Phase 2
60
Shanghai
2026-01-20
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
Fudan University
Not applicable
384
Shanghai
2025-12-15
Recruiting
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
Fuzhou, Wuhan, Shanghai, Tianjin
2025-08-18
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai
2025-07-30
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
31
Shanghai
2025-07-30
Recruiting
Dizal Pharmaceuticals
Phase 1/2
180
Shanghai
2025-07-16
Recruiting
Akeso
Phase 3
536
Shanghai
2025-07-08
Active, closed
Shanghai Chest Hospital
Phase 2/3
97
Shanghai
2025-06-03
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
50
Shanghai
2025-05-23
Recruiting
Baohui Han
Observational
508
Shanghai
2025-03-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
720
Shanghai
2025-02-24
Recruiting
Fudan University
Phase 2
34
Shanghai
2025-02-07
Recruiting
Study on the Mechanism of Acquired Resistance of Entrectinib
NCT07199959ROS1 Fusion Positive, Non Small Cell Lung Cancer
DrugEntrectinib
Fudan University
Observational
38
Shanghai
2025-01-15
Recruiting
Ruijin Hospital
Observational
40
Shanghai
2024-12-30
Recruiting
Peng Zhang
Phase 2
60
Shanghai
2024-11-07
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Active, closed
Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.
NCT07274761Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
DrugSunvozertinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
24
Shanghai
2024-10-17
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Shanghai
2024-10-16
Recruiting
A Phase Ib Study of GC101 in NSCLC
NCT06473961Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
DrugAutologous Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase 1
20
Shanghai
2024-10-14
Recruiting
Jialei Wang
Phase 2
60
Shanghai
2024-10-01
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
296
Shanghai
2024-09-30
Recruiting
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
NCT05613452Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
43
Shanghai
2024-09-29
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Not yet open
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
By invitation
Shanghai Chest Hospital
Observational
500
Shanghai
2024-08-16
Recruiting
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
NCT06311981Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
Jian Chen
Phase 2
29
Shanghai
2024-08-08
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2024-07-31
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
Shanghai Chest Hospital
Phase 2
54
Shanghai
2024-04-02
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Recruiting
Shanghai Chest Hospital
Observational
200
Shanghai
2023-12-15
Recruiting
Jian Chen
Phase 2
77
Shanghai
2023-12-07
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Active, closed
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Recruiting
Shanghai Chest Hospital
Observational
250
Shanghai
2023-10-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
40
Shanghai
2023-09-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
14
Shanghai
2023-09-04
Recruiting
Ruijin Hospital
Observational
50
Shanghai
2023-08-31
Active, closed
Fudan University
Phase 2
202
Shanghai
2023-08-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
198
Shanghai
2023-07-19
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3
242
Shanghai
2023-05-11
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Dizal Pharmaceuticals
Phase 2
60
Shanghai
2023-02-15
Active, closed
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
NCT07632365Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
Shanghai Chest Hospital
Phase 1/2
108
Shanghai
2022-10-09
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
275
Shanghai
2021-12-31
Active, closed
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Active, closed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
624
Shanghai
2021-08-11
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Haerbin, Linyi, Beijing, Shanghai
2021-08-04
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
NCT06369181Neuroendocrine Carcinoma, Non-small Cell Lung Cancer, Histology Transformation
Fudan University
Observational
50
Shanghai
2021-01-01
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
Nuvation Bio Inc.
Phase 2
173
Shanghai
2020-07-07
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Recruiting
Ruijin Hospital
Phase 1
15
Shanghai
2017-09-14
Recruiting
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
NCT03392233Breast Cancer, Prostate Cancer, Non Small Cell Lung Cancer
RenJi Hospital
Phase 2
100
Shanghai
2017-08-18
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Recruiting
Shanghai Chest Hospital
Observational
250
Shanghai
2016-07-21
Rows per page Showing 1–86 of 86
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 86 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

54 of the 86 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 20 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 86 studies
PhaseStudiesRecruitingShare
Phase 2241627.9%
Phase 1/2141016.3%
Phase 314616.3%
Observational131015.1%
Phase 113815.1%
Not applicable525.8%
Phase 2/3323.5%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Shanghai Chest Hospital126
Sichuan Baili Pharmaceutical Co., Ltd.84
Shanghai Pulmonary Hospital, Shanghai, China74
Fudan University64
Dizal Pharmaceuticals33
Ruijin Hospital33
Akeso22
Eli Lilly and Company20
Hoffmann-La Roche21
Jian Chen22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.